Bortezomib (PS-341)

Catalog No.S1013 Synonyms: LDP-341, MLM341

Bortezomib (PS-341) Chemical Structure

Molecular Weight(MW): 384.24

Bortezomib (PS-341) is a potent 20S proteasome inhibitor with Ki of 0.6 nM. It exhibits favorable selectivity towards tumor cells over normal cells.

Size Price Stock Quantity  
USD 70 In stock
USD 270 In stock
USD 670 In stock
Bulk Discount
Bulk Inquiry

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 149 Publications

25 Customer Reviews

  • Immunoblot analysis of cell lysates from the indicated cell lines treated with GNE-6776 (2 μ M for 18 h), either alone or in combination with a UAE1 inhibitor MLN-7243 (5 μ M for 45 min) or the proteasome inhibitor bortezomib (5 μ M for 45 min) as indicated.

    Nature, 2017, 550(7677):534-538. Bortezomib (PS-341) purchased from Selleck.

    Indisulam dependent degradation of RBM39 can be blocked by bortezomib, a proteasome inhibitor. Cells were pretreated with indicated concentrations of bortezomib for 2 hours, followed by 6 hours of treatment with 2 μM indisulam. The effect of bortezomib is attenuated in a bortezomib resistant cell line.

    Science, 2017, eaal3755. Bortezomib (PS-341) purchased from Selleck.

  • Wild-type mice fed as indicated were injected with vehicle (10% DMSO, pH 7.4 PBS) or bortezomib (5 mg/kg bodyweight). Livers were collected 16 hr later for quantitative PCR analysis of indicated genes (n = 4–5). *p < 0.05 bortezomib effect and #p < 0.05 Chol-Diet effect by two-way ANOVA.

    Cell, 2017, 171(5):1094-1109. Bortezomib (PS-341) purchased from Selleck.

    Effect of different proteasome inhibitors on dysferlin expression and on membrane resealing in cultured primary myoblasts. Primary myoblasts from patient 2 harboring a homozygous Arg555Trp DYSF mutation that were treated with the indicated amounts of bortezomib for 24 hours. Western blots of protein extracts were stained with anti-dysferlin antibodies and with anti–a-tubulin antibody as loading control.

    Sci Transl Med 2015 6(250), 250ra112. Bortezomib (PS-341) purchased from Selleck.

  • Pharmacologic inhibition of the proteasome blocks proplatelet formation in murine and human megakaryocytes. Human megakaryocytes were pretreated with vehicle or bortezomib, and megakaryocytes producing proplatelets (PP) were examined. Shown are representative transmission images and representative confocal images with wheat germ agglutinin (WGA; red) and phalloidin (green) staining. Scale bars: 50 um.

    J Clin Invest 2014 124(9), 3757-66. Bortezomib (PS-341) purchased from Selleck.

    Effects of NF-kB inhibition on cell proliferation and apoptosis in Foxp3cKO prostate. A. Top left panels: Representative H&E staining of PIN lesions in ventral prostates of 60-week-old PBS- or bortezomib-treated Foxp3cKO littermates. Scale bar, 50 祄. Right graph: Quantification of Ki67-positive cells identified by IHC analysis (bottom left panels) as a measure of cell proliferation, performed with Scion Image software. Horizontal lines represent the average values. The p value was determined by two-tailed t test. B. Representative western blots showing p65 and nuclear p65 (N-p65) expression in prostates at 12 hours after LPS injection in 45-week-old PBS- or bortezomib-treated mice. C. Quantification of Bcl2l1 and Traf1/2 mRNA expression as a percentage of Hprt expression measured in microdissected mouse prostate epithelial cells by qPCR at 12 hours after LPS injection in 45-week-old PBS- or bortezomib-treated mice. Horizontal lines represent the average values. The p values were determined by two-tailed t test. D. Left panels: Representative images of TUNEL assays performed on prostates from PBS- or bortezomib-treated mice at 60 weeks of age. Insets show the apoptotic cells (green) in prostate glands. Scale bar, 100 祄. Right graph: Quantification of apoptotic cells in the ventral and dorsolateral prostates of PBS- or bortezomib-treated mice at 45 and 60 weeks of age. Horizontal lines represent the average values. The p value was determined by two-tailed t test. cKO, PB4-Cre4+Foxp3flox/y; wks, weeks; B/P, ratio of the mean value from bortezomib-treated mice to the mean value in PBS-treated mice. All experiments were repeated two times. Wks, weeks.

    Cancer Res 2015 75(8), 1714-24. Bortezomib (PS-341) purchased from Selleck.

  • Immunofluorescence showing HDAC4 localization in mouse primary osteoblasts treated with vehicle or PTH alone or in the presence of bortezomib. Primary osteoblasts treated with vehicle, PTH, or PTH plus bortezomib for 2 h using anti-HDAC4 and anti-b-actin antibodies.

    J Cell Biol 2014 205(6), 771-80. Bortezomib (PS-341) purchased from Selleck.

    Inhibition of proteasome and lysosome or silencing of VCP and co-factors lead to the accumulation of OP-puro-labeled DRIPs adjacent to or within SGs. HeLa cells were co-treated for 45 min with OP-puro and arsenite (Ars.); where indicated, cells were pretreated with bortezomib (Bort.) overnight and/or ammonium chloride (NH4Cl) for 2 h 15 min. Cells were fixed and labeled with Alexa594-Azide and anti-TIA-1.

    Cell Death Differ 2014 21(12), 1838-51. Bortezomib (PS-341) purchased from Selleck.

  • Immunofluorescence analysis for Ser536 p-NF-κB cellular localization of RS4;11cells treated with CX-4945 (5 μM) and bortezomib (2.5 nM) either alone or in combination. Cells were treated, collected at 22 h and reacted with an antibody to Ser536 p-NF-κB which was revealed by a Cy3-conjugated secondary antibody. DAPI was used to label nuclei.

    Oncotarget, 2015, 51: S659-S660. Bortezomib (PS-341) purchased from Selleck.

    Control wild-type and Fmn2–/–oocytes observed at different stages of meiotic maturation [prophase I (Pro I), NEBD, 3 hours and 8 hours after NEBD] using anti-Fmn2. wt + Bortezo, wild-type oocytes treated with 0.1μM Bortezomib for 90 minutes before fixation. All oocytes were observed using the same settings and the images treated the same way (three independent experiments). Red arrows indicate cortical labeling. Scale bar: 10μm.

    Development 2011 138, 2903-2908. Bortezomib (PS-341) purchased from Selleck.

  • Cell viability of HCT116 cells treated with a single drug or with the addition of leucovorin.

    Sci Rep, 2017, 7(1):682. Bortezomib (PS-341) purchased from Selleck.

    (B–C) LNCaP (B) and LNCaP-AI (C) cells were transiently transfected with sPLA2-IIa(-800)-Luc (0.5 μg). The cells were then treated with Erlotinib (20 μM), Gefitinib (20 μM), Lapatinib (20 μM), CI-1033 (8 μM), LY294002 (20 μM) and Bortezomib (20 μM) without or with EGF (100 ng/ml) for 24 h. Luciferase assay was performed according to a standard protocol with Renilla luciferase as an internal control. Data are presented as the mean (±SD) of duplicate values of a representative experiment that was independently repeated for five times.

    Carcinogenesis 2010 31, 1948–1955. Bortezomib (PS-341) purchased from Selleck.

  • LNCaP-AI cells were starved in 1% stripped medium for 24 h. The cells were then treated with Erlotinib (20 μM), Gefitinib (20 μM), Lapatinib (20 μM), CI-1033 (8 μM), LY294002 (20 μM) and Bortezomib (20 μM) for 24 h. Cell culture medium was collected from each sample and subjected to ELISA for sPLA2-IIa. The condition medium samples were diluted 10 times for ELISA. Average of duplicate samples was converted to nanogram per milliliter against standard curve. The data represent one of five repeated experiments.

     

     

    Carcinogenesis 2010 31, 1948–1955. Bortezomib (PS-341) purchased from Selleck.

    Western blot of extracts of infected cells treated with different proteasome inhibitors at different concentrations, reacted with the indicated antibodies. p53 was used to monitor proteasome inhibition, and actin was used as a loading control.

     

     

    J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck.

  • Time window treatment with proteasome inhibitors. (A) Scheme of the experiment performed with MA104 cells exposed to virus (OSU; MOI, 3) for 1 h and analyzed at the starting point and endpoint of the indicated time window treatments with DMSO, MG132, or bortezomib. (B) Western blot of cellular lysates derived from cells infected for the indicated time periods and treated with the proteasome inhibitors or DMSO. NI, noninfected cells. Blots were reacted with the indicated antibodies; p53 was used to monitor proteasome inhibition, and actin was used as a loading control.

    J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck.

    Fluorescence analysis of viroplasm formation on NSP5-EGFP cells infected with rotavirus (OSU; MOI, 3) and treated or not treated with MG132 (10 M) or bortezomib (10 M) at different times p.i., as indicated. Cells were analyzed at the starting points (1 h, 3 h, 5 h, 7 h) and endpoints (9 h) of the inhibitor’s window treatment.

     

     

    J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck.

  • Quantification of the accumulation of viroplasms in infected NSP5 -EGFP/MA104 cells. At different times p.i., cells were treated for 4 h with DMSO or the indicated proteasome inhibitor and the number of viroplasms/cell was quantified at the starting (1 h, 3 h, 5 h; white bars) and endpoints (5 h, 7 h, 9 h) of treatment.

     

     

    J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck.

    PS-341 impairs FPV replication in A549 cells. (A and B)A549 cells were either pretreated for 1 h with different concentrations of PS-341 or with solvent only or were left untreated. Then, cells were infected with FPV at an MOI of 0.001 (A) or 0.05 (B). After virus inoculation cells were posttreated with different concentrations of PS-341. (A) At 24 h p.i. supernatants were obtained and progeny virus titers were measured by standard plaque assay. (B)Proteasome activity and the ability of PS-341 to inhibit the proteasome was determined 24 h p.i. (C) A549 cells were pretreated with 50 nM PS-341 or solvent or left untreated for 1 h. Afterwards cells were infected with FPV at an MOI of 0.0005. Subsequent to virus inoculation cells were posttreated with 50 nM PS-341 or solvent or left untreated. After the indicated times p.i.supernatants were obtained and progeny virus titers were determined by standard plaque assay. Arrow bars in all experiments represent standard deviations of three independent experiments.

    J Virol 2010 84, 9439–9451. Bortezomib (PS-341) purchased from Selleck.

  • Early steps of viral replication within the first replication cycle are affected. (A) For time-of-addition kinetics analysis, A549 cells were either left untreated or were pretreated for 10 h or 1 h with 50 nM PS-341 before infection and additionally posttreated after infection. Cells were infected with FPV at an MOI of 0.005. After virus inoculation cells were posttreated with 50 nM PS-341. Then the proteasome inhibitor was added after virus inoculation (10 h, 1 h, and 30 min) or it was added at the different times p.i. as indicated (1 h, 2 h, 4 h, 6 h, and 8 h; cells were not pretreated before infection). At 9 h p.i. supernatants were obtained and progeny virus titers were determined by standard plaque assay. Shown is one representative experiment out of three independent experiments. (B) A549 cells were pretreated with 50 nM PS-341 or left untreated for 1 h. Afterwards cells were infected with avian FPV or human PR8 at an MOI of 1. Subsequent to virus inoculation cells were posttreated with 50 nM PS-341 or left untreated. After the indicated times p.i. cells were lysed and analyzed by Western blotting for accumulation of viral proteins polymerase PB1 and matrix protein M1. Cellular protein ERK2 served as a control to demonstrate equal amounts of protein loading. Shown is one representative blot out of three independent experiments.

     

     

    J Virol 2010 84, 9439–9451. Bortezomib (PS-341) purchased from Selleck.

    A549 cells were treated with PS-341 at 50 nM for the indicated times or left untreated. Western blotting was performed with total cell lysates, using phospho-specific antibodies against JNK and the transcription factors c-Jun and ATF-2 or loading controls, respectively.

     

     

    J Virol 2010 84, 9439–9451. Bortezomib (PS-341) purchased from Selleck.

  • The stable cell line HepAD38 was incubated for 18 h in the presence of the indicated amount of Bortezomib. The medium was removed and replaced by medium containing Bortezomib dissolved in PBS. In case of the control cells the same amount of PBS was added to the medium. 4 h later this procedure was repeated and again 14 h later the supernatant was collected. The amount of viral particles was quantified by real time PCR. HBV-genome quantification was done using COBAS® AmpliPrep/COBAS® TaqMan® HBV test (Roche Diagnostics GmbH, Mannheim, Germany) according to the manufacturer’s instructions. The assay shows relative values (the value for untreated control cells was arbitrarily set as 1) that are based on three independent experiments. The cell viability was analyzed by MTT assays. For does up to 50 nM no significant effect on cell viability was observed within 18h, for 100 nM the proportion of metabolically active cells was reduced to 83%.

    J Biol Chem 2010 285, 41074-41086. Bortezomib (PS-341) purchased from Selleck.

    HLC-1 cells were treated with IFN-gamma (30 ng/ml) and Bortezomib (0-10 nM) for 3 h. After washing with PBS, the cells were cultured for another 45 h in the fresh medium. After 48 h incubation, PD-L1 expression was analysed by flow cytometry (n =3).

    Int Immunopharmacol, 2018, 54:39-45. Bortezomib (PS-341) purchased from Selleck.

  • Proteasome inhibition effect on biotinylation of MHC-Iα. (a) WB-ra of cellular extracts of HEK293 cells co-transfected with BAP-MHC-Ia and cyt-BirA (control) and, where indicated, with US2 or US11 in the absence (2) or presence of MG132 (MG; 50 μM for 4 h) or Bortezomib(Bort.; 50 μM for 4 h).

    PLoS One 2011 6, e23712. Bortezomib (PS-341) purchased from Selleck.

     

    KKU-M213 was treated with BTZ as indicated. Total cell lysate ( a) and nuclear extract (b) were prepared. Actin and γ -tubulin were loading controls for total and nuclear proteins, respectively.

    2011 Mireia Vila Gasull University of Porto. Bortezomib (PS-341) purchased from Selleck.

  • Mireia Vila Gasull University of Porto. 2011;Mireia Vila Gasull . Bortezomib (PS-341) purchased from Selleck.

Purity & Quality Control

Choose Selective Proteasome Inhibitors

Biological Activity

Description Bortezomib (PS-341) is a potent 20S proteasome inhibitor with Ki of 0.6 nM. It exhibits favorable selectivity towards tumor cells over normal cells.
Targets
20S proteasome [1]
(Cell-free assay)
0.6 nM(Ki)
In vitro

Bortezomib, a boronic acid dipeptide, is a highly selective, reversible inhibitor of the 26S proteasome which primarily functions in the degradation of mis-folded proteins and is essential for the regulation of the cell cycle. Exposure to Bortezomib has been shown to stabilize p21, p27, and p53, as well as the proapoptotic Bid and Bax proteins, caveolin-1, and inhibitor κB-α, which prevents activation of nuclear factor κB-induced cell survival pathways. Bortezomib also promotes the activation of the proapoptotic c-Jun-NH2 terminal kinase, as well as the endoplasmic reticulum stress response. Alteration of the levels of these cellular proteins leads to inhibition of proliferation, migration, and promotion of apoptosis of cancer cells. [2] Bortezomib is shown to penetrate into cells and inhibit proteasome-mediated intracellular proteolysis of long-lived proteins with a concentration that inhibits 50% of the proteolysis of ∼0.1 μM. The average growth inhibition of 50% value for Bortezomib across the entire panel of 60 cancer cell lines derived from multiple human tumors from the US National Cancer Institute (NCI) is 7 nM. Treatment of PC-3 cells with Bortezomib (100 nM) for 8 h results in the accumulation of cells in G2-M, with a corresponding decrease in the number of cells in G1. Bortezomib kills PC-3 cells at 24 and 48 hr with IC50 of 100 and 20 nM, respectively. Bortezomib induces nuclear condensation at 16–24 hr after treatment. Bortezomib treatment leads to PARP cleavage in a time-dependent manner with concentrations as low as 100 nM being effective at 24 hr. [1]
Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MCF-7 MX7DfZRwfG:6aXOgRZN{[Xl? NWLRS3BkPTBizszN NUnJUVVuPDhiaB?= NH;WbVRFVVOR M3XIPGtqdGy|IHPlcIx{KGK7IH3vdoUhfGijbjC5PUU> Mon4NVA1QTl4NEO=
OVCA 429 M3n1UGZ2dmO2aX;uJGF{e2G7 M2XabVMxOCCwTR?= MYm0PEBp MUXEUXNQ MXPEbZNzfXC2czDpcpRi[3RibYXseIlk\WyudXzhdkB1fW2xcjDzdIhmem:rZIO= M2jKblExQTl7N{[2
RPMI8226 M2TEXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWDiVXlHOTByIH7N NV;Sc3R6PDhiaB?= MnvFSG1UVw>? MXLJR|UxRTNyIH7N NFPvU4kyOTNyNkS4PS=>
Dox40 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXixNFAhdk1? NEDjUHc1QCCq MWPEUXNQ MoPGTWM2OD12MDDuUS=> M1rCWVEyOzB4NEi5
MR20 NIn2S|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\xV4kyODBibl2= NV;1N2FQPDhiaB?= NGr5e2FFVVOR MXnJR|UxRTJyIH7N NFjteIsyOTNyNkS4PS=>
LR5 Mk\kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2XmOFExOCCwTR?= Mn7xOFghcA>? NXjJW4dzTE2VTx?= M{i1OmlEPTB;MkCgcm0> NHfMSVAyOTNyNkS4PS=>
U266 MonUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjCRWkyODBibl2= NYrwWFZxPDhiaB?= MkniSG1UVw>? NELwbW5KSzVyPUOgcm0> MV6xNVMxPjR6OR?=
IM-9 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILrVo4yODBibl2= Mn\UOFghcA>? MW\EUXNQ MYrJR|UxRTZibl2= M3LjbFEyOzB4NEi5
Hs Sultan M1fEbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlXpNVAxKG6P MV20PEBp NVHJSGRpTE2VTx?= M1m4SGlEPTB;MkCgcm0> MoXXNVE{ODZ2OEm=
PAM-LY2 NVjwTXlPTnWwY4Tpc44hSXO|YYm= M{jTVFExOCCwTR?= M4DvRVEzKGh? MVnEUXNQ NHjte3RKdmirYnn0d{BPTi4QulKgZYN1cX[jdHnvci=> M2PWdVEyOzVyOUGz
PAM 212 M4TBZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\oT4QyODBibl2= NEH4fXI4OiCq M4nx[2ROW09? Mm[2TY5pcWKrdIOgZ4VtdCC4aXHibYxqfHl? MmfVNVE{PTB7MUO=
PAM-LY2 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUexNFAhdk1? MojMO|IhcA>? MlOzSG1UVw>? M4XCU2lvcGmkaYTzJINmdGxidnnhZoltcXS7 M4O4O|EyOzVyOUGz
B4B8 NH;IdppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWqxNFAhdk1? M1zCblczKGh? MXHEUXNQ NVSyWVFjUW6qaXLpeJMh[2WubDD2bYFjcWyrdIm= M2XTTlEyOzVyOUGz
B7E3 MnXvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVvWNIRkOTByIH7N M4fSW|czKGh? NYfRSIR[TE2VTx?= NUXpcHJxUW6qaXLpeJMh[2WubDD2bYFjcWyrdIm= MWixNVM2ODlzMx?=
UM-SCC-9 M3TqSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYexNFAhdk1? MmDxO|IhcA>? MoLTSG1UVw>? NWnTZVQ3UW6qaXLpeJMh[2WubDD2bYFjcWyrdIm= MlfWNVE{PTB7MUO=
UM-SCC-11B NH7oV3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX7nb3hlOTByIH7N MVe3NkBp MnyzSG1UVw>? NX22RXQyUW6qaXLpeJMh[2WubDD2bYFjcWyrdIm= NX7ReZQ2OTF|NUC5NVM>
H460 MV3GeY5kfGmxbjDBd5NigQ>? Mln1NVAh|ryP MXKyOEBp MYfEUXNQ M4DUdWlv\HWlZYOgRoNtNTJicHjvd5Bpd3K7bHH0bY9vKGGwZDDjcIVifmGpZTDjc5Jz\WyjdHXkJJdqfGhiR{KtUUBxcGG|ZTDhdpJme3R? MXGxNlQ6OjFzNx?=
U266 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MorEOVAxKG6pL33s MWG0PEBp M3q2XWROW09? MWrJcohq[mm2czDj[YxtKGe{b4f0bC=> MmPQNVI3OzF4MUm=
ARH77 M3;LeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUXzZopXPTByIH7nM41t NVTHNnNtPDhiaB?= NUjNe2h3TE2VTx?= NHTTcFhKdmirYnn0d{Bk\WyuIHfyc5d1cA>? MUGxNlY{OTZzOR?=
WAD-1 NIWwUnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mln1OVAxKG6pL33s NGXOdm81QCCq Mne0SG1UVw>? NInaeGdKdmirYnn0d{Bk\WyuIHfyc5d1cA>? Mny1NVI3OzF4MUm=
U266/LR7 NI[0d3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1\3UlUxOCCwZz;tcC=> NF3OXGw1QCCq NWn4Z|hqTE2VTx?= NF3UdGxKdmirYnn0d{Bk\WyuIHfyc5d1cA>? M4ntVlEzPjNzNkG5
U266/dox4 MlnkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MofrOVAxKG6pL33s M2nsblQ5KGh? NXu2S|dZTE2VTx?= MnXlTY5pcWKrdIOgZ4VtdCCpcn;3eIg> NHrPWXcyOjZ|MU[xPS=>
RPMI8226/LR5 NGP5UllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\zU|UxOCCwZz;tcC=> Mlu4OFghcA>? NYG0blV6TE2VTx?= MUPJcohq[mm2czDj[YxtKGe{b4f0bC=> MVOxNlY{OTZzOR?=
H460 M1\qeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{fHWVExKM7:TR?= MYO3NkBp MULEUXNQ NV7qdlZYUUN3ME2xNFAhdk1? M3XBd|EzPjNzNkKw
H358 MkjOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFfuNXEyOCEQvF2= M1vCWlczKGh? M3j2bGROW09? M3\NUGlEPTB;N{Cgcm0> NX7WNGRVOTJ4M{G2NlA>
H322 NELIRmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlfqNVAh|ryP NH;nXJY4OiCq M3fQbmROW09? MkW1TWM2OD14MkCgcm0> M4C1TVEzPjNzNkKw
H460 NFz2V2pHfW6ldHnvckBCe3OjeR?= NI\ONWoyODBibl2= M3Tie|I1KGh? MlnSSG1UVw>? M1\0WWlv\HWlZYOgS|IuVS2yaHHz[UBienKnc4SgZY5lKHS3YoXsbY4h[XO|ZX3icJku\Gm|YYPz[Y1jdHl? M17P[FEzPjNzNkKw
LNCap-Pro5 NV7US3k1TnWwY4Tpc44hSXO|YYm= NG\4XJQyKM7:TR?= MYq0JIg> MYrEUXNQ Ml\5V5Ri[mmuaYrld{BxPTN? M1GyUlE1PjF{NUOy
T29 NX75[oZrSXCxcITvd4l{KEG|c3H5 MkTWOVAhdk1? M3O5TlQ5KGhi M1rZRWROW09? M4nqbmlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? NFrIRYkyPjd5OEG3PS=>
T29Kt1 M3LDUGFxd3C2b4Ppd{BCe3OjeR?= MVG1NEBvVQ>? NGXoXXE1QCCqIB?= MVjEUXNQ NX\tZ3F3UW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= MlXFNVY4PzhzN{m=
HCT116 NHW5W5VCeG:ydH;zbZMhSXO|YYm= MkCzOVAhdk1? MlnmOFghcCB? MljGSG1UVw>? MXfJcoR2[2W|IHPlcIwh[XCxcITvd4l{ MnrRNVY4PzhzN{m=
HKe-3 NVrCdG91SXCxcITvd4l{KEG|c3H5 M1rxXlUxKG6P NUnxN|k4PDhiaDC= NXO0bY5QTE2VTx?= MU\JcoR2[2W|IHPlcIwh[XCxcITvd4l{ NWPHWHVHOTZ5N{ixO|k>
NB-1691 NUO3cHdjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVTsTGd2OSEQvF2= NG\lPYQ4OiCq M4XEVGlvcGmkaYTzJINmdGxicILvcIln\XKjdHnvckB1dyB3JR?= M320eVE4Pjh7Nki0
CHLA-255 MnXwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo[zNUDPxE1? MXS3NkBp MXXJcohq[mm2czDj[YxtKHC{b3zp[oVz[XSrb36geI8hOiV? M37OdVE4Pjh7Nki0
SK-N-AS MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHy3RZcyKM7:TR?= MlT2O|IhcA>? MoXITY5pcWKrdIOgZ4VtdCCycn;sbYZmemG2aX;uJJRwKDFyJR?= MUSxO|Y5QTZ6NB?=
NB-1691 NX7FT2llTnWwY4Tpc44hSXO|YYm= M4DQSVExKG6P NWPZSFlwOjRiaB?= NWnlSlhZW2mpbnnmbYNidnSueTDy[YR2[2W|IHPlcIx{KGmwIITo[UBIOC:JMTDwbIF{\Q>? M2nmblE4Pjh7Nki0
CHLA-255 M1PR[WZ2dmO2aX;uJGF{e2G7 MknaNVAhdk1? M1PmblI1KGh? MmPGUY9l\XO2bImgdoVlfWOnczDj[YxteyCrbjD0bIUhTzBxR{GgdIhie2V? M3TZWlE4Pjh7Nki0
RPMI 8226 NGq4enpHfW6ldHnvckBCe3OjeR?= M{[5RVIxKG6P MmfPPEBp MUTTbYdvcW[rY3HueIx6KGWwaHHuZ4V{KE6ILd86RkBi[3Srdnn0fS=> Mn;wNVk1OzZyNUC=
MM.1S M4P5OGZ2dmO2aX;uJGF{e2G7 NV\MU5BxOjBibl2= MoroPEBp NXPnTmZVW2mpbnnmbYNidnSueTDlcohidmOnczDOSk3PwkJiYXP0bZZqfHl? MmDFNVk1OzZyNUC=
U266 NID5XnFHfW6ldHnvckBCe3OjeR?= NHL1[nUzOCCwTR?= NXj3SGxSQCCq NFPCcYxUcWewaX\pZ4FvfGy7IHXubIFv[2W|IF7GMe67SiCjY4Tpeol1gQ>? MorXNVk1OzZyNUC=
OPM1 NYDifm11TnWwY4Tpc44hSXO|YYm= NW\GPXdVOjBibl2= MnvHPEBp NIL0RmNUcWewaX\pZ4FvfGy7IHXubIFv[2W|IF7GMe67SiCjY4Tpeol1gQ>? M2L0S|E6PDN4MEWw
INA6 MmPuSpVv[3Srb36gRZN{[Xl? NIfTcXMzOCCwTR?= MXq4JIg> MmTtV4lodmmoaXPhcpRtgSCnbnjhcoNmeyCQRj5OvmIh[WO2aY\peJk> MnvoNVk1OzZyNUC=
OPM2 MnfqSpVv[3Srb36gRZN{[Xl? M4\C[lIxKG6P MWi4JIg> NHrW[VVUcWewaX\pZ4FvfGy7IHXubIFv[2W|IF7GMe67SiCjY4Tpeol1gQ>? M{PjclE6PDN4MEWw
RPMI 8226 NVm3OGlXTnWwY4Tpc44hSXO|YYm= NUjx[2UzOjBibl2= MVG4JIg> NWGxN41vUW6mdXPld{BFVkFic4nueIhme2m| M1fXeFE6PDN4MEWw
BaF/3 NUH5WYl5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVHr[nhyOTByIH7N MXu0PEBp MULJR|UxRTZwMjDuUS=> MVqyNFMxPTZ7Mh?=
BaF/3-p210 NYm2R3ROT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDGOWs5OTByIH7N MYO0PEBp M3myV2lEPTB;ND63JI5O MVGyNFMxPTZ7Mh?=
TCC-S MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVn3RotVOTByIH7N M1PXeFQ5KGh? NYrySWk5UUN3ME2yMlghdk1? NXXZTHF[OjB|MEW2PVI>
BaF/3 MkfSSpVv[3Srb36gRZN{[Xl? NGmxXmI3KG6P NVHXelZPPDhiaB?= NWDUNVVFUW6mdXPld{BiKGe{ZXH0JGcyKGOnbHytZ5lkdGViYYLy[ZN1 Mny5NlA{ODV4OUK=
BaF/3-p210 NU\a[INJTnWwY4Tpc44hSXO|YYm= M3G5PVYhdk1? MVq0PEBp M{fVfGlv\HWlZYOgZUB{dGmpaISgS|Eh[2WubD3jfYNt\SCjcoLld5Q> NInpUYkzODNyNU[5Ni=>
BaF/3-p210 MUXGeY5kfGmxbjDBd5NigQ>? NYjIXm5[PiCwTR?= NFXvSJczPCCq M3jtNnJm\HWlZYOgeIhmKHCqb4PwbI9zgWyjdHnvckBidmRidHjlJIFkfGm4aYT5JI9nKFKk NYjVdoJGOjB|MEW2PVI>
Raji MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEnxU48yKM7:TR?= MUWyOEBp M{TLbXJm\HWlZYOgZ4VtdCC4aXHibYxqfHoEoB?= MXKyNVE4ODl6OB?=
LCL-1 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoD3NUDPxE1? NXPl[mlROjRiaB?= MWrS[YR2[2W|IHPlcIwhfmmjYnnsbZR6yqB? MkTDNlEyPzB7OEi=
LCL-2 M4XpZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV:xJO69VQ>? M4HsSFI1KGh? M3na[HJm\HWlZYOgZ4VtdCC4aXHibYxqfHoEoB?= MoPXNlEyPzB7OEi=
BJAB NE\GdWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHtW5oyKM7:TR?= MXeyOEBp MVjS[YR2[2W|IHPlcIwhfmmjYnnsbZR6yqB? Mn;pNlEyPzB7OEi=
SNT-13 NHvEfJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\ObmR1OSEQvF2= MlTtNlQhcA>? MUfS[YR2[2W|IHPlcIwhfmmjYnnsbZR6yqB? MnfBNlEyPzB7OEi=
SNT-16 MkDiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnW3NUDPxE1? NXPNPINYOjRiaB?= MVzS[YR2[2W|IHPlcIwhfmmjYnnsbZR6yqB? NGPPUZgzOTF5MEm4PC=>
Jurkat NV33eG5OT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkTPNUDPxE1? MofCNlQhcA>? Mo[0VoVlfWOnczDj[YxtKH[rYXLpcIl1gcLi MmLoNlEyPzB7OEi=
KAI-3 M1rIN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGPS[|YyKM7:TR?= MVKyOEBp NI\vbY5T\WS3Y3XzJINmdGxidnnhZoltcXS7wrC= NWfPPHlMOjFzN{C5PFg>
SNK-6 NIPNSHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXmxJO69VQ>? Ml[5NlQhcA>? M1\3U3Jm\HWlZYOgZ4VtdCC4aXHibYxqfHoEoB?= NY\ES4JXOjFzN{C5PFg>
KHYG-1 NGGxUHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI[wWVgyKM7:TR?= NUXxXnRIOjRiaB?= M1rFPHJm\HWlZYOgZ4VtdCC4aXHibYxqfHoEoB?= MXGyNVE4ODl6OB?=
SNT-16 NXHZclVGSXCxcITvd4l{KEG|c3H5 NFjnNpQyKM7:TR?= M3nGXVYhcA>? M{HBb2lv\HWlZYOgZ4VtdCCjcH;weI9{cXN? NH[1fnYzOTF5MEm4PC=>
Jurkat NXHUUoo4SXCxcITvd4l{KEG|c3H5 M2LIUFEh|ryP NIjocHM3KGh? MnXHTY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? NIniWG0zOTF5MEm4PC=>
KAI-3 NU\WWJNqSXCxcITvd4l{KEG|c3H5 NV7aSYlJOSEQvF2= MV:2JIg> NUWzUW1JUW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= MYOyNVE4ODl6OB?=
KHYG-1 MYfBdI9xfG:|aYOgRZN{[Xl? M3qzTVEh|ryP MnPtOkBp NVq2cYhXUW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= M1jyT|IyOTdyOUi4
SNT-13 NHvHN25CdnSrdnnyZYwhSXO|YYm= NH\CZmMyKM7:TR?= NHf0OGwzPCCq NIHk[IRKdmS3Y3XzJIx6fGmlIHnu[oVkfGmxbjDv[kBGSlZ? MVeyNVE4ODl6OB?=
SNT-16 MY\BcpRqfmm{YXygRZN{[Xl? MVSxJO69VQ>? NWn6UFVxOjRiaB?= NFLnWVRKdmS3Y3XzJIx6fGmlIHnu[oVkfGmxbjDv[kBGSlZ? NXTUNHpmOjFzN{C5PFg>
KAI-3 MmXzRY51cX[rcnHsJGF{e2G7 M{SxT|Eh|ryP NUXLTYZqOjRiaB?= MoqzTY5lfWOnczDsfZRq[yCrbn\lZ5Rqd25ib3[gSWJX NUfNe4ZqOjFzN{C5PFg>
SNK-6 NHT6NZFCdnSrdnnyZYwhSXO|YYm= NHfBUXUyKM7:TR?= NHfhVlYzPCCq NFvOZohKdmS3Y3XzJIx6fGmlIHnu[oVkfGmxbjDv[kBGSlZ? MXyyNVE4ODl6OB?=
RAW 264.7 NVzLW2lkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIDuWHgyODBibl2= M3TSWVQ5KGh? NI\NNnJT\WS3Y3XzJINmdGxidnnhZoltcXS7wrC= MmrxNlI1OjdzNUS=
A375 M3zafmFxd3C2b4Ppd{BCe3OjeR?= MmPDNVAhdk1? MoKwNlQhcA>? MkXaTY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? NEXpXFMzOzB5OUC4Ny=>
BLM Mn;yRZBweHSxc3nzJGF{e2G7 NUfHNIxDOTBibl2= MXGyOEBp NYXiXFVKUW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= NU[2UJBtOjNyN{mwPFM>
A375 MV3BeZRweGijZ4mgRZN{[Xl? MlvnNVAhdk1? MV6xNkBp NFvaTmdKdmS3Y3XzJIZwem2jdHnvckBw\iCjdYTvdIhi\2:|b33ldy=> NFX1NJUzOzB5OUC4Ny=>
BLM MofORZV1d3CqYXf5JGF{e2G7 M2nxSVExKG6P MnjwNVIhcA>? NInhVnBKdmS3Y3XzJIZwem2jdHnvckBw\iCjdYTvdIhi\2:|b33ldy=> MnjLNlMxPzlyOEO=
H1299 MmDLRZBweHSxc3nzJGF{e2G7 NIfFTGQ5OCCwTR?= M{HJZlI1KGh? MVzEUXNQ MkjxV4Vve2m2aYrld{BPW0OOQzDj[YxteyC2bzDNV2Mu\GW{aY\l[EBqSzlvaX7keYNm\CCjcH;weI9{cXN? MUSyOVMzOzZ7Mx?=
Hut-78 MlfaSpVv[3Srb36gRZN{[Xl? NV7yNZZJOTByIH7N NUjaXppSOjRiaB?= NEPKOIFFVVOR NHHFRpFFd3ewcnXneYxifGW|IGTHSk3PujFiYX7kJGlNNTFyIHX4dJJme3Orb36= M{Dob|I2PjhzM{O1
H9 MnqxSpVv[3Srb36gRZN{[Xl? M4jxeVExOCCwTR?= M4WwNlI1KGh? NGrlSZhFVVOR M2n5NmRwf26{ZXf1cIF1\XNiVFfGMe6zOSCjbnSgTWwuOTFiZYjwdoV{e2mxbh?= NF7meFIzPTZ6MUOzOS=>
HH NV:zSoh5TnWwY4Tpc44hSXO|YYm= NH7zeHUyODBibl2= NULYfoJKOjRiaB?= NVLablVQTE2VTx?= NWXNOYlp\G:5boLl[5Vt[XSnczDUS2Yu|rJzIHHu[EBKVC1zMjDlfJBz\XO|aX;u NFfYVowzPTZ6MUOzOS=>
Hut-78 NVfYe48{VWmpcnH0bY9vKEG|c3H5 NHrHV|QyODBibl2= NGTjUHgzPCCq MWjEUXNQ NIr5dFZT\WS3Y3XzJINmdGxibXnndoF1cW:wIHL5JFgx6oDVOUCl MlLDNlU3QDF|M{W=
HH NVLMbIhwVWmpcnH0bY9vKEG|c3H5 NX3CcJE6OTByIH7N MmPnNlQhcA>? Ml:1SG1UVw>? MoPTVoVlfWOnczDj[YxtKG2rZ4LheIlwdiCkeTC4NQKBmzlzJR?= M1f5dFI2PjhzM{O1
U937 MVfGeY5kfGmxbjDBd5NigQ>? NHezN4syODBibl2= NIX2PIE3KGh? NFH6NWVKdmS3Y3XzJGlNNThiZYjwdoV{e2mxbjDpckBNWFNvc4TpcZVt[XSnZDDVPVM4KG2jY4LvdIhi\2W| M4fQe|I2PzlzNEe3
human PBMC NH7afHhHfW6ldHnvckBCe3OjeR?= Ml3uNVAxKG6P NFz1VmEzPCCq NFm3OVZKdmS3Y3XzJGlNNThicnXs[YF{\Q>? MXyyOVc6OTR5Nx?=
ES6 NU\NeY03T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIrvS3JKSzVyPUCuNFAzOSCwTR?= Mlm1V2FPT0WU
SK-UT-1 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7CSXVWUUN3ME2wMlE3OyCwTR?= M4PPTXNCVkeHUh?=
SH-4 NUnWZWN3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXHH[|hYUUN3ME2wMlE4OyCwTR?= NXT5PGRRW0GQR1XS
TE-9 NUe1ZZNDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFjBSYxKSzVyPUCuNVgzKG6P NXTkc3ZoW0GQR1XS
A253 NVn3NIV[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGrJUGFKSzVyPUCuNlA5KG6P NVXvdYdKW0GQR1XS
no-10 NGHzbZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTBwMkGgcm0> MVjTRW5ITVJ?
MMAC-SF MkfYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU\ocZdSUUN3ME2wMlIyPiCwTR?= MojhV2FPT0WU
A101D NWPHfmlTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3PncmlEPTB;MD6yNlUhdk1? NWDNUFlmW0GQR1XS
NTERA-S-cl-D1 NGrOd2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYfES2ExUUN3ME2wMlI1OyCwTR?= MVLTRW5ITVJ?
8-MG-BA MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkTjTWM2OD1yLkK1JI5O MWnTRW5ITVJ?
KNS-42 M2DNN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLoTWM2OD1yLkK1PEBvVQ>? NHrUbY9USU6JRWK=
LXF-289 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnzFTWM2OD1yLkK2PUBvVQ>? NIKxOFBUSU6JRWK=
OVCAR-4 NV\ENmZ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHjZpVKSzVyPUCuNlg6KG6P Mn3aV2FPT0WU
LOUCY NXHVd2FPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MorGTWM2OD1yLkK5N{BvVQ>? NGqxeFBUSU6JRWK=
BB65-RCC NH3vdXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHvEPINKSzVyPUCuN|A1KG6P NGDQWYZUSU6JRWK=
D-542MG NXfwbmU5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3z3cmlEPTB;MD6zNlkhdk1? Mn3UV2FPT0WU
ONS-76 M4\HUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGPLZlFKSzVyPUCuN|Mhdk1? NH7t[oxUSU6JRWK=
BB30-HNC NG\wSnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk\4TWM2OD1yLkOzOUBvVQ>? NXXTRldTW0GQR1XS
KS-1 M1H2PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlLaTWM2OD1yLkO0JI5O M3nKfnNCVkeHUh?=
A388 NIrRTJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEWxNHNKSzVyPUCuN|U3KG6P M3HRXHNCVkeHUh?=
ES8 MoXBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXriOIszUUN3ME2wMlQhdk1? MXnTRW5ITVJ?
MZ2-MEL NEmzdpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTBwNEC3JI5O MX\TRW5ITVJ?
HCC2998 NFfuRVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUfDTFBHUUN3ME2wMlQyOiCwTR?= NHXzR2ZUSU6JRWK=
D-247MG MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVHDUlY{UUN3ME2wMlQyOyCwTR?= NULaNopVW0GQR1XS
ACN MkfXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWLBOHJ[UUN3ME2wMlQyPyCwTR?= MoO1V2FPT0WU
LB2518-MEL NWXSfIx2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MonZTWM2OD1yLkSyOUBvVQ>? MmTzV2FPT0WU
ES1 NHqzSHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M33XSmlEPTB;MD60N{BvVQ>? M1Kz[3NCVkeHUh?=
HCE-T MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEPLdG1KSzVyPUCuOFM6KG6P NHXNbWZUSU6JRWK=
OS-RC-2 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2jhVWlEPTB;MD60OEBvVQ>? NFrBXIRUSU6JRWK=
MFH-ino NVXqNWNNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmO4TWM2OD1yLkS0N{BvVQ>? MXvTRW5ITVJ?
OCUB-M M1LsTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX7rR4Y1UUN3ME2wMlQ1PyCwTR?= NUHM[oFDW0GQR1XS
CP66-MEL M3vUfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWjJdJp{UUN3ME2wMlQ4OyCwTR?= M4TMb3NCVkeHUh?=
LB771-HNC NUnHdmlNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXLXfXZKUUN3ME2wMlQ4PCCwTR?= NX2yXHR4W0GQR1XS
DSH1 NHrvOmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTBwNEigcm0> M4TYcXNCVkeHUh?=
HUTU-80 M{\QTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV\Ec|BSUUN3ME2wMlU{OyCwTR?= MXzTRW5ITVJ?
CESS NUnMNItmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXuzbYdEUUN3ME2wMlU{QCCwTR?= M3\EUHNCVkeHUh?=
NCI-H747 NGfsRo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEHuT4xKSzVyPUCuOVM6KG6P NGfKUVFUSU6JRWK=
HT-144 NFTocWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV;JR|UxRTBwNUe2JI5O NWPkfpA6W0GQR1XS
COLO-829 NUPCfYc1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVHMemZDUUN3ME2wMlYyPCCwTR?= NYDHSIRqW0GQR1XS
A4-Fuk M4nqWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4n0SmlEPTB;MD62NlMhdk1? M1[3b3NCVkeHUh?=
GI-ME-N M2XXZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1TxXGlEPTB;MD62N|Qhdk1? M1y0[nNCVkeHUh?=
LB831-BLC MoPvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGrP[IhKSzVyPUCuOlQyKG6P NEfmZmdUSU6JRWK=
HOP-62 NUexbVM3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkTuTWM2OD1yLk[0O{BvVQ>? NIfyWY1USU6JRWK=
BB49-HNC M2TVUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVPJTWtuUUN3ME2wMlY2OiCwTR?= MkD1V2FPT0WU
D-336MG MnXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoXmTWM2OD1yLk[1O{BvVQ>? M1PwO3NCVkeHUh?=
TK10 MmfXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVXF[ZZVUUN3ME2wMlY4QSCwTR?= NXvVTXo4W0GQR1XS
Ramos-2G6-4C10 MlP4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3NeFVzUUN3ME2wMlY6OyCwTR?= MljvV2FPT0WU
LB373-MEL-D NITp[FZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjiN3lGUUN3ME2wMlchdk1? M4jxcHNCVkeHUh?=
SF126 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTBwN{CxJI5O MXnTRW5ITVJ?
UACC-257 NInrTIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\PeGRGUUN3ME2wMlcyKG6P NWOyNXROW0GQR1XS
KINGS-1 Ml7lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoH3TWM2OD1yLkeyNkBvVQ>? NHj4UWZUSU6JRWK=
LS-513 NW[0N3oxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3TqPWlEPTB;MD63N|khdk1? MUfTRW5ITVJ?
GI-1 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlu1TWM2OD1yLke2OEBvVQ>? NYSzR3BbW0GQR1XS
ES7 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2TvcmlEPTB;MD63OlYhdk1? NFXQfVZUSU6JRWK=
LB2241-RCC MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\t[lVGUUN3ME2wMlgxPCCwTR?= MnKzV2FPT0WU
D-263MG MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE\Tc2xKSzVyPUCuPFA4KG6P MX3TRW5ITVJ?
SW684 NHS4epFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4rPOmlEPTB;MD64NlEhdk1? MVzTRW5ITVJ?
ML-2 M{TNPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXK1[5ZWUUN3ME2wMlgzOSCwTR?= NWf2SXhXW0GQR1XS
SK-LMS-1 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmrqTWM2OD1yLki1OEBvVQ>? MkCyV2FPT0WU
TE-5 NHu0TY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV7USplYUUN3ME2wMlg3PSCwTR?= NFXsd21USU6JRWK=
QIMR-WIL NIDtcZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmLMTWM2OD1yLki4PUBvVQ>? M3f3UXNCVkeHUh?=
NCI-H1355 M3XPdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTBwOEm1JI5O NUDSZnMzW0GQR1XS
SNB75 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmPzTWM2OD1yLkmxNkBvVQ>? M3rIOHNCVkeHUh?=
RXF393 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmSyTWM2OD1yLkmxOEBvVQ>? MYXTRW5ITVJ?
IST-MEL1 NXPnWZg1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoTsTWM2OD1yLkmxO{BvVQ>? MlfjV2FPT0WU
SF268 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHfKblNKSzVyPUCuPVI{KG6P NX32NWZTW0GQR1XS
KALS-1 NF7VNJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3rTWM2OD1yLkmyOUBvVQ>? NXn6VYZUW0GQR1XS
HC-1 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEX6eJVKSzVyPUCuPVc2KG6P MnP1V2FPT0WU
SW872 NV3Sdpl1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NILjRnRKSzVyPUCuPVk3KG6P NH;OS|VUSU6JRWK=
PSN1 MkW2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEXZeVVKSzVyPUGuNFEhdk1? NYDhcnNtW0GQR1XS
TE-1 MlzzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTFwMEOgcm0> NIiyeZhUSU6JRWK=
TE-10 NGPV[pJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1r6fGlEPTB;MT6wN{BvVQ>? MlS0V2FPT0WU
RKO M3;FeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXX6enhWUUN3ME2xMlA3KG6P MX\TRW5ITVJ?
LC-2-ad M1flZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRTFwMEigcm0> M{HnOnNCVkeHUh?=
SK-MM-2 NGXpZnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3vIUWlEPTB;MT6wPUBvVQ>? NVjKb2R4W0GQR1XS
VA-ES-BJ MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlnRTWM2OD1zLkC5JI5O M1u4XXNCVkeHUh?=
MZ7-mel MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWXJR|UxRTFwMEmgcm0> M1OxZXNCVkeHUh?=
D-392MG M1PyXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NELCO4tKSzVyPUGuNUBvVQ>? MXjTRW5ITVJ?
CCRF-CEM MmraS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLmTWM2OD1zLkGzJI5O NXzpZVlVW0GQR1XS
EM-2 NEnpOWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3zkd2lEPTB;MT6xOkBvVQ>? M1TLd3NCVkeHUh?=
HAL-01 NVvjVXp5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUTiR3ZlUUN3ME2xMlE5KG6P MUTTRW5ITVJ?
TE-8 M4P0UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnMXmM2UUN3ME2xMlE6KG6P NGXyXFBUSU6JRWK=
NCI-H1882 NU\VOXZIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTFwMjDuUS=> NIP1bpJUSU6JRWK=
Daudi NGnhVIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFTVVVRKSzVyPUGuNlIhdk1? M{jQeXNCVkeHUh?=
BL-41 MmnSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jRN2lEPTB;MT6yOUBvVQ>? Mme2V2FPT0WU
SR MlL2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4fBe2lEPTB;MT6yOUBvVQ>? M4PkbnNCVkeHUh?=
KM12 Mo[3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4DpRWlEPTB;MT6yO{BvVQ>? MnLpV2FPT0WU
K5 NVTrb2ZFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4HEcWlEPTB;MT6yPEBvVQ>? M2HlW3NCVkeHUh?=
A3-KAW Mn75S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoTMTWM2OD1zLkK4JI5O NFH6OmNUSU6JRWK=
CMK MnS2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3G1fmlEPTB;MT6yPUBvVQ>? NFnGWGtUSU6JRWK=
Calu-6 MlzjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmnsTWM2OD1zLkK5JI5O NWHLO4Z6W0GQR1XS
IST-SL2 NYG1XFRlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIr6U2FKSzVyPUGuN|Ehdk1? NVPaTGI{W0GQR1XS
OPM-2 NHHOUo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmP6TWM2OD1zLkOzJI5O M2q4ZXNCVkeHUh?=
DU-4475 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MojtTWM2OD1zLkO2JI5O MX7TRW5ITVJ?
ECC12 MnizS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3LwVmlEPTB;MT6zO{BvVQ>? MVPTRW5ITVJ?
L-540 MkmzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|UxRTFwM{egcm0> M3z3U3NCVkeHUh?=
CAS-1 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NITvZotKSzVyPUGuN|chdk1? NHu3coJUSU6JRWK=
PF-382 NFP3[XBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M17MfmlEPTB;MT60O{BvVQ>? M1HyU3NCVkeHUh?=
LS-411N MojNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWXZdZk2UUN3ME2xMlU{KG6P NXLlSo9iW0GQR1XS
NCI-H69 NXfvZY1HT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MljTTWM2OD1zLkW0JI5O M3nSOHNCVkeHUh?=
NB12 M3eyWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTFwNU[gcm0> Ml63V2FPT0WU
HEL MnL5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2j3W2lEPTB;MT62NUBvVQ>? NFmxSHlUSU6JRWK=
GCIY NX7vdnZNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;2b2lEPTB;MT62NkBvVQ>? MYXTRW5ITVJ?
EHEB NVTiRXZpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{[0UGlEPTB;MT62O{BvVQ>? MlXwV2FPT0WU
TGBC1TKB MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|UxRTFwN{Ggcm0> Mlq3V2FPT0WU
KURAMOCHI MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHJTWM2OD1zLkeyJI5O M131fHNCVkeHUh?=
U-266 NEfEWVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MojwTWM2OD1zLke2JI5O NUjWUFlrW0GQR1XS
LC4-1 MlLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NITIdIRKSzVyPUGuO|khdk1? MmnVV2FPT0WU
NCI-H2126 NWDFNnkyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTFwODDuUS=> M{LmNXNCVkeHUh?=
NCI-H1092 NGfwb2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHzZT5BKSzVyPUGuPEBvVQ>? NYrZW|lqW0GQR1XS
GB-1 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVT1T2JsUUN3ME2xMlgyKG6P NXfqdZY2W0GQR1XS
MV-4-11 MmrWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{PZcmlEPTB;MT64NkBvVQ>? MnGzV2FPT0WU
Becker M2r3Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUTQZWtxUUN3ME2xMlg{KG6P MmjPV2FPT0WU
MPP-89 NHXnbHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWXJR|UxRTFwOEmgcm0> M3LRV3NCVkeHUh?=
BE-13 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVXoXHVZUUN3ME2xMlk{KG6P MnGwV2FPT0WU
697 MknJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVm5fYFCUUN3ME2xMlk6KG6P M{\ldXNCVkeHUh?=
NKM-1 MnHuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVPiXHd3UUN3ME2yJI5O NWn3UmN4W0GQR1XS
NB13 NGewPINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkTxTWM2OD1{IH7N MUnTRW5ITVJ?
LS-123 MmXPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTJwMEKgcm0> NVvaVHR3W0GQR1XS
NB17 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXPyR21vUUN3ME2yMlA1KG6P NYrCd5R6W0GQR1XS
LAN-6 MmnuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIH0VnRKSzVyPUKuNFUhdk1? M{HoZ3NCVkeHUh?=
EW-24 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXXiSWFbUUN3ME2yMlA5KG6P NYD5PGhTW0GQR1XS
NOS-1 MmPXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHfubWRKSzVyPUKuNVEhdk1? M2rJVnNCVkeHUh?=
BL-70 NWTaNYR{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{G2VmlEPTB;Mj6xNkBvVQ>? MlnoV2FPT0WU
GT3TKB NV3Vb4lYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWX1enVDUUN3ME2yMlEzKG6P Ml61V2FPT0WU
HH NYS0UlBUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXjDcFVoUUN3ME2yMlE{KG6P NXjIdZhrW0GQR1XS
KE-37 Mm\4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;VTWM2OD1{LkGzJI5O MnHLV2FPT0WU
MOLT-4 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTJwMUOgcm0> Mo[xV2FPT0WU
EKVX NFH3OIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M17PTmlEPTB;Mj6xOEBvVQ>? MnHTV2FPT0WU
KGN MkO4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4XEPWlEPTB;Mj6xOUBvVQ>? NXnwNW1IW0GQR1XS
ES4 NIrKdphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmXITWM2OD1{LkG2JI5O M4O5cnNCVkeHUh?=
SJSA-1 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTJwMkGgcm0> MY\TRW5ITVJ?
KMOE-2 M3fMVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHvXTmxKSzVyPUKuNlMhdk1? MnLiV2FPT0WU
NB5 M33OWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnTSTWM2OD1{LkK3JI5O MUjTRW5ITVJ?
BC-1 Ml;rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHO2NJdKSzVyPUKuN|Ehdk1? NITEVolUSU6JRWK=
NB10 M1HyNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHjCdGxKSzVyPUKuN|Ihdk1? NInVPG9USU6JRWK=
RPMI-8226 NX\5SZZxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGDUb|FKSzVyPUKuN|Uhdk1? MX3TRW5ITVJ?
SCC-3 NXX0fZRXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVPFcJZSUUN3ME2yMlM4KG6P NXjubWRSW0GQR1XS
ARH-77 NUjwOo15T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVL6VZdKUUN3ME2yMlM5KG6P MmPHV2FPT0WU
NCI-H748 M1XWb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTJwM{mgcm0> Ml[2V2FPT0WU
KU812 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILuNIlKSzVyPUKuOFIhdk1? MWfTRW5ITVJ?
NCI-H64 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHf2SWlKSzVyPUKuOFQhdk1? NH\hOXdUSU6JRWK=
NB69 M3jmcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NInnbFZKSzVyPUKuOFYhdk1? M4m0bHNCVkeHUh?=
KNS-81-FD MkXvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{TRb2lEPTB;Mj60PEBvVQ>? NVTUbYxFW0GQR1XS
LB1047-RCC MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnXKTWM2OD1{LkW3JI5O NH;xcGRUSU6JRWK=
EB-3 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTJwNk[gcm0> NHu0V2xUSU6JRWK=
Mo-T M2XTTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlLSTWM2OD1{Lke0JI5O NIjyd5JUSU6JRWK=
EW-16 NHn4THBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH65XnVKSzVyPUKuO|Uhdk1? Mo[0V2FPT0WU
CTV-1 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEP4OYZKSzVyPUKuPEBvVQ>? NX:yOFVDW0GQR1XS
ETK-1 MkCxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnvVTWM2OD1{Lki0JI5O NYfBZYNVW0GQR1XS
C2BBe1 M4PYd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGfMUnlKSzVyPUKuPFkhdk1? M{OxVnNCVkeHUh?=
MOLT-16 NF\NOmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4fkd2lEPTB;Mj64PUBvVQ>? MX7TRW5ITVJ?
SW954 M2fwXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoHLTWM2OD1{Lkmgcm0> NFi3NHhUSU6JRWK=
HT NFzZcIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXPoSph7UUN3ME2zMlAzKG6P MoHtV2FPT0WU
KARPAS-299 M1vnXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2fIeWlEPTB;Mz6wOkBvVQ>? MVHTRW5ITVJ?
MONO-MAC-6 M{j0TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGjNd5hKSzVyPUOuNUBvVQ>? NGTYV4JUSU6JRWK=
CGTH-W-1 MlnUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHnUdJhKSzVyPUOuNUBvVQ>? NUXQTFlLW0GQR1XS
SK-PN-DW MlS4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{nLWGlEPTB;Mz6xOEBvVQ>? M4LH[HNCVkeHUh?=
CW-2 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{n3dWlEPTB;Mz6yNUBvVQ>? NWrmW2ZnW0GQR1XS
SK-N-DZ NH:1O3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn\YTWM2OD1|LkK2JI5O NWTiNoh2W0GQR1XS
NEC8 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTNwM{Wgcm0> M4XNOXNCVkeHUh?=
LB996-RCC MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFnG[HNKSzVyPUOuOEBvVQ>? MVLTRW5ITVJ?
DB MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2TofmlEPTB;Mz60NUBvVQ>? MVXTRW5ITVJ?
TE-15 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NULEW|E1UUN3ME2zMlQ{KG6P MkPuV2FPT0WU
COR-L88 NWrtN4RST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTNwNEegcm0> NEPoeIFUSU6JRWK=
LAMA-84 NHyzdYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHXJZ2VKSzVyPUOuOFkhdk1? NHvKVmtUSU6JRWK=
MEG-01 MoXYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYflRmFuUUN3ME2zMlQ6KG6P NYrpclNYW0GQR1XS
LOXIMVI MmjrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1y5fmlEPTB;Mz61JI5O M2fyR3NCVkeHUh?=
RPMI-8402 M37tcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\LTWM2OD1|LkWgcm0> MnzaV2FPT0WU
KARPAS-45 NW\6W457T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2GxfGlEPTB;Mz61OEBvVQ>? M3zVOHNCVkeHUh?=
HCC1187 NYLDUoxZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\MTHdKSzVyPUOuOVQhdk1? M3HyW3NCVkeHUh?=
MZ1-PC MnfaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2rn[GlEPTB;Mz61OEBvVQ>? NEPZOVhUSU6JRWK=
no-11 NEHNblFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmjWTWM2OD1|LkW1JI5O NEmxWXpUSU6JRWK=
EVSA-T NIXRWWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPsWGdKSzVyPUOuOkBvVQ>? NVq2eog1W0GQR1XS
DJM-1 NXu2d3FPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEPxRXlKSzVyPUOuOlMhdk1? NYX3VHRYW0GQR1XS
COLO-684 M4\4cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlfvTWM2OD1|Lk[2JI5O MUXTRW5ITVJ?
NMC-G1 M2XYU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVq1[oYyUUN3ME2zMlY5KG6P MX3TRW5ITVJ?
LC-1F Ml7uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLwTWM2OD1|Lke0JI5O M3TL[nNCVkeHUh?=
RL95-2 NHiwcWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3XOTmlEPTB;Mz63PUBvVQ>? NH7xNG9USU6JRWK=
COLO-320-HSR NHLTcFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEnBe2VKSzVyPUOuPVIhdk1? M3[2fnNCVkeHUh?=
RCC10RGB MnLES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NID5ZppKSzVyPUOuPVMhdk1? NYfae3dpW0GQR1XS
HD-MY-Z MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\Pc|ZnUUN3ME2zMlk{KG6P MnrVV2FPT0WU
NCI-H2141 Ml3CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\iTWM2OD12LkC1JI5O NV3sZW83W0GQR1XS
K-562 M4HLXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXXJR|UxRTRwMUKgcm0> NULaN2RQW0GQR1XS
NCI-H1648 NYDwWVdFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTRwMUOgcm0> NXTLcFVCW0GQR1XS
OMC-1 M{LOdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjWVIkzUUN3ME20MlE5KG6P Mmq4V2FPT0WU
LB647-SCLC NFHo[GpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnf1TWM2OD12LkKyJI5O MYXTRW5ITVJ?
TE-12 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVTobXFTUUN3ME20MlI2KG6P MlrVV2FPT0WU
NOMO-1 NVnCTplZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmHzTWM2OD12LkOzJI5O MVjTRW5ITVJ?
Raji M{fPe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnPMTWM2OD12LkS2JI5O MmTtV2FPT0WU
NALM-6 Mn3PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2fQWWlEPTB;ND60PUBvVQ>? NGPJVXdUSU6JRWK=
HL-60 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVmwVFJ[UUN3ME20MlY4KG6P MWDTRW5ITVJ?
IST-SL1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEfFcphKSzVyPUSuOlghdk1? M2rvS3NCVkeHUh?=
MHH-PREB-1 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4PKb2lEPTB;ND64OkBvVQ>? MoXSV2FPT0WU
MHH-NB-11 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTRwOUGgcm0> NXiy[Ik{W0GQR1XS
JiyoyeP-2003 MmnFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoLrTWM2OD13IH7N MnP5V2FPT0WU
SBC-1 Mn:1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml7LTWM2OD13LkCxJI5O NEW1e5RUSU6JRWK=
CHP-126 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVeyUHhUUUN3ME21MlA3KG6P NV7PU|lJW0GQR1XS
LU-139 NFOzV4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NID0V|JKSzVyPUWuNVMhdk1? MlT6V2FPT0WU
NCI-SNU-5 MmLFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFnKdoJKSzVyPUWuNVchdk1? M4m1SHNCVkeHUh?=
SW962 NYPpUXFsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml3TTWM2OD13LkKxJI5O Mn7WV2FPT0WU
EW-1 M3XCTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTVwM{Ggcm0> MYXTRW5ITVJ?
NCI-H1417 NEfjeXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRTVwNUGgcm0> NV70PWJDW0GQR1XS
LU-65 NF3KOGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3;1RmlEPTB;NT64OEBvVQ>? MljrV2FPT0WU
D-502MG NXnsPWhVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTZwM{egcm0> MYjTRW5ITVJ?
BC-3 M4fkNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlnOTWM2OD14Lk[xJI5O M1zDNHNCVkeHUh?=
GDM-1 Ml;4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|UxRTZwN{egcm0> NV7yfnpmW0GQR1XS
NCI-H2196 M3mzfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoHOTWM2OD14Lkigcm0> NFrOTlNUSU6JRWK=
NB1 NIjHT2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTZwOEigcm0> NY[yfGU5W0GQR1XS
NCI-H345 NULiO4o1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTdwMjDuUS=> MorPV2FPT0WU
SU-DHL-1 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGDCXoVKSzVyPUeuNlQhdk1? MYnTRW5ITVJ?
JVM-2 M1Tadmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1jybWlEPTB;Nz6yPEBvVQ>? M4rwUXNCVkeHUh?=
LU-134-A MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|UxRTdwM{mgcm0> MYXTRW5ITVJ?
NCI-H1694 NY\EfZZPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{Tk[2lEPTB;Nz61PEBvVQ>? NVXhbYhVW0GQR1XS
NCI-SNU-16 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXPwcWRQUUN3ME23MlY2KG6P MXvTRW5ITVJ?
L-363 NUfXeo5ST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoTxTWM2OD15Lkegcm0> NGO3fmJUSU6JRWK=
KG-1 M1frN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTdwOUSgcm0> MVjTRW5ITVJ?
MN-60 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWPMXnZsUUN3ME24MlE1KG6P MoDFV2FPT0WU
NB6 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPWTWM2OD16LkS4JI5O MnzWV2FPT0WU
MLMA M3zveGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRThwOEWgcm0> NFrIPYlUSU6JRWK=
ATN-1 MkDXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4TyRmlEPTB;OD64PUBvVQ>? M1fQZ3NCVkeHUh?=
SK-NEP-1 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{PkRWlEPTB;OT6wNUBvVQ>? NEi0RplUSU6JRWK=
DMS-114 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2TpS2lEPTB;OT62NkBvVQ>? M3jye3NCVkeHUh?=
CTB-1 MkjNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGfJSHJKSzVyPUmuOlchdk1? MnPpV2FPT0WU
NCI-H2081 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTFyLkC5JI5O NFG2eHlUSU6JRWK=
ES5 Mm\hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEjoNnRKSzVyPUGwMlM5KG6P MUTTRW5ITVJ?
HCC1599 M{T4SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTFzLkmxJI5O NYPJUm5YW0GQR1XS
NCI-H23 NFq0PWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\kZmlEPTB;MUKuNVIhdk1? MoLwV2FPT0WU
NCI-H1581 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTF{LkK4JI5O NHXTOYhUSU6JRWK=
JVM-3 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml;hTWM2OD1zMj65PUBvVQ>? NHTVXW9USU6JRWK=
NCI-SNU-1 NF3iblNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTF|LkG5JI5O NXjBXFlJW0GQR1XS
NB7 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoDZTWM2OD1zNT65NkBvVQ>? MYfTRW5ITVJ?
JAR MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\DTWM2OD1zNj6xN{BvVQ>? NEfmWo9USU6JRWK=
TGW NGjmZmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUG5TVBJUUN3ME2xOk41QCCwTR?= NW\MT2FOW0GQR1XS
U-87-MG M3TsWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnnZWhKSzVyPUG2Mlc3KG6P MnXyV2FPT0WU
NCI-H1436 NFe1SFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmraTWM2OD1zNz6wNUBvVQ>? MlT6V2FPT0WU
GOTO M3zVSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFW3UHdKSzVyPUG3MlA3KG6P NXfrUGUxW0GQR1XS
COLO-800 NUPSN4RLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEXudo1KSzVyPUG3MlY1KG6P NEDEe2JUSU6JRWK=
MFM-223 M{DadWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoXOTWM2OD1zNz65NUBvVQ>? MXrTRW5ITVJ?
EW-18 NWDMSWpPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGC1NIZKSzVyPUG3Mlk3KG6P MWHTRW5ITVJ?
NB14 NG[xbVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnywTWM2OD1zNz65PEBvVQ>? MXjTRW5ITVJ?
EB2 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{K3TWlEPTB;MUiuNFghdk1? MkDUV2FPT0WU
EoL-1- M3[0V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{DXZWlEPTB;MUiuN|Ehdk1? M3\hR3NCVkeHUh?=
NCCIT Mmi0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1K1d2lEPTB;MUiuN|Yhdk1? MmnPV2FPT0WU
DG-75 NUm0eW1TT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlv1TWM2OD1zOD62NUBvVQ>? NWHzUJJOW0GQR1XS
HCC2218 NIr1U4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHNSZhKSzVyPUG5MlUhdk1? MU\TRW5ITVJ?
TE-6 NWj4[ZJyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIX0SWpKSzVyPUKwMlA5KG6P NEjtWpZUSU6JRWK=
SF539 NWD1OGtZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYfJR|UxRTJyLk[3JI5O Mn\WV2FPT0WU
NCI-H446 MoLIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTJzLkG4JI5O MlfRV2FPT0WU
IST-MES1 NHLXV3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnzHTWM2OD1{Mj63O{BvVQ>? Ml;GV2FPT0WU
NCI-H82 M{GzW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2PFVmlEPTB;MkOuNFIhdk1? NXe2c3JkW0GQR1XS
HCC2157 NGnEemdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFrpWG1KSzVyPUKzMlE{KG6P NF\kR|RUSU6JRWK=
EW-12 NUe5OXptT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmrkTWM2OD1{Mz6xO{BvVQ>? MoPVV2FPT0WU
SIMA Mn\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlO1TWM2OD1{Mz6zPEBvVQ>? NFvGZ|lUSU6JRWK=
DOHH-2 NUfkOJVtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTJ|LkS1JI5O MX;TRW5ITVJ?
IM-9 M3j1cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkPBTWM2OD1{Mz61OEBvVQ>? MmL2V2FPT0WU
EC-GI-10 M{S5TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jhfmlEPTB;MkSuNlMhdk1? NGrtTWlUSU6JRWK=
HDLM-2 M1vRWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXSfo0zUUN3ME2yOE42PCCwTR?= M1;wVHNCVkeHUh?=
LS-1034 MmLuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3SwS2lEPTB;MkWuO|Uhdk1? MnrCV2FPT0WU
REH NGC4dGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{nBfWlEPTB;Mk[uOFEhdk1? MnXxV2FPT0WU
LU-165 NF;ZNlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVHJR|UxRTJ4LkeyJI5O MYTTRW5ITVJ?
NH-12 MmnRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTJ5Lk[3JI5O MkjIV2FPT0WU
WSU-NHL NXzpWoFMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWPFSnFOUUN3ME2yPE4{QSCwTR?= MUDTRW5ITVJ?
ECC4 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3vPSGlEPTB;MkiuO|khdk1? Mon4V2FPT0WU
OCI-AML2 NUnrZ|FmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFWwZpRKSzVyPUK5MlY6KG6P NHzhcWtUSU6JRWK=
EW-3 MkDTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV;JR|UxRTNyLkW5JI5O NV7DRWZmW0GQR1XS
NCI-H526 NYDLXnpDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEDucnJKSzVyPUOyMlU1KG6P NWnmU3A{W0GQR1XS
NCI-H719 NEm4[mtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFu0WlJKSzVyPUO0MlMyKG6P NIPPbGVUSU6JRWK=
KARPAS-422 NWTkfoxmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2fLV2lEPTB;M{WuNFQhdk1? MoPFV2FPT0WU
SK-MEL-1 M2[xe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVT0bG5EUUN3ME2zOU4yPyCwTR?= MonnV2FPT0WU
ES3 MkPHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIrDUFhKSzVyPUO1MlE6KG6P MUHTRW5ITVJ?
UACC-812 NW\6SFdoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGLyN4xKSzVyPUO1MlQ1KG6P MVHTRW5ITVJ?
C8166 NX;lZm5UT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUX0Nmt3UUN3ME2zOU44KG6P Mn[zV2FPT0WU
MDA-MB-134-VI MlWzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml7zTWM2OD1|NT64O{BvVQ>? NXjxco1bW0GQR1XS
D-283MED Mo[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3f3[WlEPTB;M{euO|khdk1? MULTRW5ITVJ?
SHP-77 MmPkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGTvR41KSzVyPUO4MlA{KG6P MWrTRW5ITVJ?
NCI-H2227 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;nO2JqUUN3ME20NE41QSCwTR?= NUfHZVF2W0GQR1XS
SKM-1 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnTUTWM2OD12Mj62N{BvVQ>? NVXTN3JHW0GQR1XS
L-428 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTR|Lki2JI5O M2LLUXNCVkeHUh?=
RPMI-6666 NYrxd2V6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTR3Lki5JI5O MkPZV2FPT0WU
NCI-H716 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\p[WRKSzVyPUS4MlgyKG6P MUXTRW5ITVJ?
DMS-79 MmnaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIq0UFJKSzVyPUWwMlcyKG6P NVLve2VnW0GQR1XS
RS4-11 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTVyLki4JI5O MXLTRW5ITVJ?
NCI-H720 Ml3WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTVzLkGxJI5O M3;j[XNCVkeHUh?=
MC-CAR MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2e5PGlEPTB;NUGuOVIhdk1? NUn1ZWNvW0GQR1XS
TALL-1 NIrE[FVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEP5SYlKSzVyPUWzMlkyKG6P M4PVbnNCVkeHUh?=
NCI-N87 NVe4dHQ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTV2LkG4JI5O MYrTRW5ITVJ?
P30-OHK NF;2TZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTV2Lk[xJI5O MnjYV2FPT0WU
LP-1 NIftXI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTZzLkK4JI5O MkS1V2FPT0WU
YT MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEDrOYtKSzVyPU[xMlghdk1? NH7QdpJUSU6JRWK=
MRK-nu-1 MnnYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTZzLkiyJI5O M1vX[HNCVkeHUh?=
BT-474 NYnJNo9VT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\BdIx[UUN3ME22OUBvVQ>? MojCV2FPT0WU
NCI-H322M NILsV|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3XRb2lEPTB;Nk[uNVEhdk1? NXflVm05W0GQR1XS
NCI-H128 M4W5bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPETWM2OD15ND63O{BvVQ>? MY\TRW5ITVJ?
KMS-12-PE M{fGeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIC2T|dKSzVyPUe2MlI1KG6P NVfZdFJ4W0GQR1XS
KP-N-YS M1TWUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\FTWM2OD15Nj63OEBvVQ>? M4m3R3NCVkeHUh?=
ALL-PO NVLkXmtkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\5TWM2OD15Nz62OkBvVQ>? M2LYO3NCVkeHUh?=
EW-13 M3PuRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXz5WGRuUUN3ME23O{44PiCwTR?= NFLEXFlUSU6JRWK=
EW-11 Mk\qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4TvSmlEPTB;N{iuOVIhdk1? NVzLUpRRW0GQR1XS
SK-N-FI NITzZm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVew[VRzUUN3ME24NE4zKG6P M2PCcnNCVkeHUh?=
CAL-148 MkL1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXfmO4pyUUN3ME24NU45PCCwTR?= NFrjR2RUSU6JRWK=
RL Ml\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF3CT|lKSzVyPUi2MlA6KG6P M2nyOHNCVkeHUh?=
AM-38 MmfXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXnrZpcxUUN3ME24PE4xQCCwTR?= M{jm[HNCVkeHUh?=
RH-1 NYPnRlY4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkjETWM2OD17OT64OUBvVQ>? MnvmV2FPT0WU
NCI-H1770 M2nwT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRTFyMj60PUBvVQ>? NVT0dohnW0GQR1XS
SIG-M5 NF7XSmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;I[XVPUUN3ME2xNFUvODZibl2= NFL3UIFUSU6JRWK=
GR-ST M4noWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\PWmlEPTB;MUGzMlM1KG6P MWrTRW5ITVJ?
ST486 M1njcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfKXFBKSzVyPUGxOE4xPiCwTR?= Ml7oV2FPT0WU
NCI-H1650 M2GwSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUfYVFN7UUN3ME2xNVUvOjlibl2= NFjtSZVUSU6JRWK=
MHH-CALL-2 MoLxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRTFzNT63JI5O M17acHNCVkeHUh?=
BV-173 M3H0TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTF{Mj63NUBvVQ>? M{nIZ3NCVkeHUh?=
MC116 NH\aVplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlHSTWM2OD1zNEiuPFUhdk1? M1S0OXNCVkeHUh?=
NCI-H524 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4HvbWlEPTB;MUW5MlEhdk1? M{LLe3NCVkeHUh?=
SCLC-21H MnTDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUD6XGtyUUN3ME2xOVkvPDFibl2= MVjTRW5ITVJ?
NCI-H1304 MkfnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2DE[mlEPTB;MU[5MlIyKG6P NHnvWWtUSU6JRWK=
NCI-H510A NIjYe|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWXJR|UxRTF6NT6zO{BvVQ>? MVHTRW5ITVJ?
NCI-H209 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\SS3BKSzVyPUG5Ok42OiCwTR?= MnLMV2FPT0WU
KM-H2 NETKOnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn\zTWM2OD1zOUeuNFUhdk1? M3rBZnNCVkeHUh?=
NCI-H1395 MnvaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTJzMD6xN{BvVQ>? M1nvZ3NCVkeHUh?=
NCI-H1155 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlz4TWM2OD1{M{CuN|Ihdk1? NYDTVZpvW0GQR1XS
COR-L279 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWjpW3VVUUN3ME2yOVIvOTdibl2= NYfOd2R3W0GQR1XS
NCI-H1299 NXHVeG44T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTJ4MT63NUBvVQ>? M2W3SXNCVkeHUh?=
EW-22 M2jyS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEKwVWtKSzVyPUK2N{44PSCwTR?= MVHTRW5ITVJ?
SK-MEL-2 NE\3cZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3LqR2lEPTB;MkixMlkhdk1? M3i5WXNCVkeHUh?=
KASUMI-1 M1;2[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NED0OVJKSzVyPUK4N{4xPSCwTR?= MlrhV2FPT0WU
NCI-H187 NH:4SmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTJ6Nz6wPEBvVQ>? MXfTRW5ITVJ?
NCI-H2171 M1iyXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGXhPWFKSzVyPUK4PE46OiCwTR?= Mn6wV2FPT0WU
LNCaP-Clone-FGC NHO1XZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFflNnJKSzVyPUK5OU4zPiCwTR?= M4\DV3NCVkeHUh?=
NCI-H1522 NVjPNHpzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnfETWM2OD1|MEeuNFUhdk1? MlnkV2FPT0WU
SCH NIrZdFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV3BdldDUUN3ME2zNlIvOjJibl2= MVjTRW5ITVJ?
THP-1 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\CU3ZsUUN3ME2zNlIvPiCwTR?= NVu4Z|E{W0GQR1XS
SNU-C1 M2fNNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTN4Mj6wPUBvVQ>? NE\vcIZUSU6JRWK=
CA46 NYnic5M3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTN5Mz62N{BvVQ>? M1LHdHNCVkeHUh?=
NCI-H1963 MnzNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYfKUWYyUUN3ME2zPFYvOTlibl2= NIHzfndUSU6JRWK=
DEL MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTN7MT6yO{BvVQ>? MYLTRW5ITVJ?
TUR MnjXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTN7Nj62NUBvVQ>? Mli0V2FPT0WU
NCI-H226 Ml:1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHHYPZVKSzVyPUSwN{4zOyCwTR?= MUPTRW5ITVJ?
COLO-668 NVG4XXRFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2\D[GlEPTB;NECzMlU4KG6P MVjTRW5ITVJ?
CPC-N NESyZ|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGnrOolKSzVyPUSwN{44PyCwTR?= NFfEb5BUSU6JRWK=
NCI-H889 NV[1PGRJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4HvWGlEPTB;NE[xMlkzKG6P MWDTRW5ITVJ?
J-RT3-T3-5 Mo\3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXTDW3ZbUUN3ME21N|IvPTdibl2= MUDTRW5ITVJ?
MSTO-211H NWjVSXZrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmnwTWM2OD13N{SuNlYhdk1? MXHTRW5ITVJ?
SCC-15 NIf3T3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYD3eI1SUUN3ME22OlcvPDdibl2= M{nF[XNCVkeHUh?=
SUP-T1 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRTZ6Nj6wOEBvVQ>? M16xb3NCVkeHUh?=
DMS-153 NH\BOXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFGz[G1KSzVyPUe0Ok45OyCwTR?= NUTrbHJCW0GQR1XS
MS-1 NIPUPJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPPcVBKSzVyPUe1PU41OiCwTR?= M1fX[HNCVkeHUh?=
TC-YIK M2L6OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVfYVmNRUUN3ME23PFEvODFibl2= NUnBXYRsW0GQR1XS
RPMI-8866 M2DVXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4nqVGlEPTB;MUCwOk4zQCEQvF2= MnjPV2FPT0WU
KY821 M3zRTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWLEd4s4UUN3ME2xNFM3NjB2IN88US=> NHvOfY5USU6JRWK=
P31-FUJ M{P3U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoX0TWM2OD1zMUGyMlc2KM7:TR?= M4q4ZnNCVkeHUh?=
COLO-824 MlmzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1vQXmlEPTB;MUK2NU44QCEQvF2= M3TzR3NCVkeHUh?=
U-698-M Ml7XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2rZWmlEPTB;MkK2Nk4yPSEQvF2= M1jHN3NCVkeHUh?=
TE-441-T MkjGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTJ3MkGuO{DPxE1? M37mNnNCVkeHUh?=
IMR-5 M1LmR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYfmRVVyUUN3ME2zOFA6NjZ{IN88US=> MXrTRW5ITVJ?
NCI-H1838 M4XFU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHjnUXJKSzVyPUSxPFYvOzJizszN NXTMR25LW0GQR1XS

... Click to View More Cell Line Experimental Data
In vivo The anticancer effects of bortezomib as a single agent have been demonstrated in xenograft models of multiple myeloma, adult T-cell leukemia, lung, breast, prostate, pancreatic, head and neck, and colon cancer, and in melanoma. [2] Oral bortezomib 1.0 mg/ kg daily for 18 days causes tumor growth delays, as well as a decrease in the number of metastases in the Lewis lung cancer model. Bortezomib at a single dose of up to 5 mg/kg significantly decreased the surviving fraction of breast tumor cells. Bortezomib 1.0 mg/kg administrated weekly for 4 weeks reduces tumor growth by 60% in murine xenograft models of prostate cancer. 1.0 mg/kg Bortezomib administration for 4 weeks results in a 72% or 84% reduction in pancreatic cancer murine xenografts growth, as well as an increase in tumor cell apoptosis. 1.0 mg/kg Bortezomib treatment results in significant inhibition of human plasmacytoma xenograft growth, increase in tumor cells apoptosis and overall survival, and a decrease in tumor angiogenesis. [3]

Protocol

Kinase Assay:

[4]
+ Expand

Kinetic Methods:

In a typical kinetic run, 2.00 mL of assay buffer (20 mM HEPES, 0.5 mM EDTA, 0.035% SDS, pH 7.8) and Suc-Leu-Leu-Val-Tyr-AMC in DMSO are added to a 3 mL fluorescence cuvette, and the cuvette is placed in the jacketed cell holder of a fluorescence spectrophotometer. Reaction temperature is maintained at 37℃ by a circulating water bath. After the reaction solution has reached thermal equilibrium (5 minutes), 1 μL−10 μL of the stock enzyme solution is added to the cuvette. Reaction progress is monitored by the increase in fluorescence emission at 440 nm (λex= 380 nm) that accompanies cleavage of AMC from peptide-AMC substrates.
Cell Research:

[5]
+ Expand
  • Cell lines: Human multiple myeloma cells line U266
  • Concentrations: ~10 μM
  • Incubation Time: 2 days
  • Method:

    The inhibitory effect of Bortezomib on cell growth is assessed by measuring MTT dye absorbance of the cells. Cells from 48-hour cultures are pulsed with 10 μL of 5 mg/mL MTT to each well for the last 4 hour of 48-hour cultures, followed by 100 μL of isopropanol containing 0.04 N HCl. Absorbance is measured at 570 nm using a spectrophotometer.


    (Only for Reference)
Animal Research:

[3]
+ Expand
  • Animal Models: Human plasmacytoma xenografts RPMI 8226
  • Formulation: Saline
  • Dosages: 1 mg/kg
  • Administration: i.v. twice weekly for 4 weeks, then once weekly
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 76 mg/mL (197.79 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+ddH2O
For best results, use promptly after mixing. 		5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 384.24
Formula

C19H25BN4O4
CAS No. 179324-69-7
Storage powder
in solvent
Synonyms LDP-341, MLM341

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03136146 Recruiting Hematopoietic/Lymphoid Cancer|Acute Lymphoblastic Leukemia|Lymphoblastic Lymphoma|Burkitt Leukemia/Lymphoma M.D. Anderson Cancer Center August 9 2017 Phase 2
NCT02195479 Active not recruiting Multiple Myeloma Janssen Research & Development LLC December 9 2014 Phase 3
NCT01449344 Active not recruiting Mantle Cell Lymphoma Prof. Dr. M. Dreyling (co-chairman)|Klinikum der Universitaet Muenchen Grosshadern|ClinAssess GmbH|GELARC Service de Pharmacovigilance Pierre Benite|European Mantle Cell Lymphoma Network May 9 2009 Phase 3
NCT00703664 Completed Recurrent Mantle Cell Lymphoma|Recurrent Non-Hodgkin Lymphoma National Cancer Institute (NCI) July 9 2008 Phase 2
NCT01965977 Recruiting Diffuse Large B Cell Lymphoma Samsung Medical Center|Janssen LP April 8 2015 Phase 2
NCT01818752 Completed Multiple Myeloma Amgen July 8 2013 Phase 3

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    On your website, it is mentioned that Bortezomib should be prepared at a concentration of 5 mg/ml in 2% DMSO/30% PEG300/ddH2O for in vivo use. But on the product sheet we received with the compound, it is mentioned: 5mg/ml in 0.5% methylcellulose, 0.2% tween 80. So which is the correct preparation buffer?

  • Answer:

    S1013 Bortezomib in 2% DMSO+30% PEG 300+ddH2O at 5 mg/ml is a clear solution, and it in 0.5% methylcellulose+0.2% Tween 80 is a suspension. Please choose the suitable vehicle according to your administration route. When you prepare the clear solution, please dissolve Bortezomib in DMSO first, make sure it dissolves well, warm it up to 45 degree and/or sonicate if necessary, then add PEG, mix well, and finally add water.

selleck catalog

Proteasome Signaling Pathway Map

Proteasome Inhibitors with Unique Features

  • Pan Proteasome Inhibitor

    Ixazomib (MLN2238) : β5 site, IC50=3.4 nM; β1 site, IC50=31 nM; β2 site, IC50=3500 nM.

  • FDA-approved Proteasome Inhibitor

    Carfilzomib (PR-171) : Approved by FDA for multiple myeloma.

  • Newest Proteasome Inhibitor

    Oprozomib (ONX 0912) : Orally bioavailable inhibitor for CT-L activity of 20S proteasome β5/LMP7 with IC50 of 36 nM/82 nM.

  • Classic Proteasome Inhibitor

    ONX-0914 (PR-957) : Selective immunoproteasome inhibitor with minimal cross-reactivity for the constitutive proteasome.

Related Proteasome Products

  • VR23 New

    VR23 is a potent proteasome inhibitor with IC50 of 1 nM, 50-100 nM, and 3 μM for trypsin-like proteasomes, chymotrypsin-like proteasomes, and caspase-like proteasomes, respectively.

  • Calpeptin New

    Calpeptin is a potent, cell-permeable calpain inhibitor with ID50 of 52 nM, 34 nM, 138 nM, and 40 nM for Calpain I (porcine erythrocytes), Calpain II (porcine kidney), Papainb, and Calpain I (human platelets), respectively.

  • Marimastat (BB-2516) New

    Marimastat (BB-2516) is a broad spectrum matrix metalloprotease (MMP) inhibitor for MMP-9, MMP-1, MMP-2, MMP-14 and MMP-7 with IC50 of 3 nM, 5 nM, 6 nM, 9 nM and 13 nM, respectively. Phase 3.

  • MG-132

    MG132 is a potent cell-permeable proteasome and calpain inhibitor with IC50s of 0.1 and 1.2 μM for the inhibition of proteasome and calpain, respectively.

  • Carfilzomib (PR-171)

    Carfilzomib (PR-171) is an irreversible proteasome inhibitor with IC50 of <5 nM in ANBL-6 cells, displayed preferential in vitro inhibitory potency against the ChT-L activity in the β5 subunit, but little or no effect on the PGPH and T-L activities.

  • Ixazomib (MLN2238)

    MLN2238 inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome with IC50 and Ki of 3.4 nM and 0.93 nM in cell-free assays, respectively, also inhibits the caspase-like (β1) and trypsin-like (β2) proteolytic sites, with IC50 of 31 and 3500 nM. Phase 3.

    Features:A first-in-class proteasome inhibitor that has improved pharmacokinetics (PK), pharmacodynamics(PD), and antitumor activity in preclinical studies.

  • ONX-0914 (PR-957)

    ONX-0914 (PR-957) is a potent and selective immunoproteasome inhibitor with minimal cross-reactivity for the constitutive proteasome in a cell-free assay.

    Features:The first highly selective, small molecule inhibitor of the immunoproteasome. Potential use in cancer and autoimmune diseases (e.g. rheumatoid arthritis, inflammatory bowel disease, and lupus).

  • Ixazomib Citrate (MLN9708)

    Ixazomib Citrate (MLN9708) immediately hydrolyzed to MLN2238, the biologically active form, on exposure to aqueous solutions or plasma. MLN2238 inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome with IC50/Ki of 3.4 nM/0.93 nM in cell-free assays, less potent to β1 and little activity to β2. Phase 3.

    Features:The 1st oral proteasome inhibitor in early stage clinical trials for Multiple Myeloma.

  • Celastrol

    Celastrol is a potent proteasome inhibitor for the chymotrypsin-like activity of a purified 20S proteasome with IC50 of 2.5 μM.

    Features:A potent antioxidant and anti-inflammatory drug.

  • Oprozomib (ONX 0912)

    Oprozomib (ONX 0912) is an orally bioavailable inhibitor for CT-L activity of 20S proteasome β5/LMP7 with IC50 of 36 nM/82 nM. Phase 1/2.

Tags: buy Bortezomib (PS-341) | Bortezomib (PS-341) supplier | purchase Bortezomib (PS-341) | Bortezomib (PS-341) cost | Bortezomib (PS-341) manufacturer | order Bortezomib (PS-341) | Bortezomib (PS-341) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID